|
gptkbp:instanceOf
|
gptkb:drug
5α-reductase inhibitor
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:ATCCode
|
G04CB02
|
|
gptkbp:brand
|
gptkb:Avodart
|
|
gptkbp:CASNumber
|
164656-23-9
|
|
gptkbp:contraindication
|
children
pregnancy
women of childbearing potential
|
|
gptkbp:developer
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
5 weeks
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C27H30F6N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dutasteride
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits type I and type II 5α-reductase
|
|
gptkbp:meltingPoint
|
242–250 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
gptkb:DB01126
5293726
6918293
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
decreased libido
gynecomastia
erectile dysfunction
ejaculation disorders
|
|
gptkbp:synonym
|
GI198745
|
|
gptkbp:UNII
|
87G6M6A2L5
|
|
gptkbp:usedFor
|
gptkb:benign_prostatic_hyperplasia
androgenetic alopecia
|
|
gptkbp:bfsParent
|
gptkb:finasteride
|
|
gptkbp:bfsLayer
|
6
|